Skip to main content

According to CMS plans announced Tuesday, the proposed CMS National Coverage Determination (NCD) would cover approved monoclonal antibodies targeting amyloid through coverage with evidence development (CED). To date, the only such approved treatment is aducanumab, and the move from CMS would sharply limit the number of beneficiaries eligible for the pricey therapy.  Click here for more information.